Quarterly ResultAug 6, 2026, 07:13 AM
REGENXBIO Q2 Net Income $22.7M; Cash Runway into Q4 2027
AI Summary
REGENXBIO reported a net income of $22.7 million for Q2 2026, a significant improvement from a net loss of $70.9 million in the prior year. Revenues increased to $108.0 million, primarily due to a $100 million milestone payment from AbbVie. The company extended its cash runway into Q4 2027 with over $200 million in new capital, including a public offering and milestone payment. Key operational highlights include RGX-202 BLA submission on track for Q3 2026 and pivotal data for sura-vec expected in Q4 2026.
Key Highlights
- Net income for Q2 2026 was $22.7 million, compared to a $70.9 million loss in Q2 2025.
- Total revenues for Q2 2026 were $108.0 million, up from $21.4 million in Q2 2025.
- Pro forma cash, cash equivalents, and marketable securities were $313 million as of June 30, 2026.
- Cash runway extended into Q4 2027 with over $200 million new capital in July 2026.
- RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026.
- Topline data from sura-vec pivotal wet AMD studies expected in Q4 2026.
- RGX-121 BLA resubmission for Hunter syndrome on track for Q3 2026.
- R&D expenses decreased to $56.1 million in Q2 2026 from $59.5 million in Q2 2025.
Price Impact
More from RGNX